(DRRX) Durect - Ratings and Ratios
Larsucosterol, POSIMIR, PERSERIS, Methydur
DRRX EPS (Earnings per Share)
DRRX Revenue
Description: DRRX Durect
Durect Corporation is a biopharmaceutical company that leverages its epigenetic regulator program to develop innovative medicines. The companys pipeline is led by larsucosterol, a promising small molecule that plays a crucial role in regulating lipid metabolism, stress, and inflammatory responses, as well as cell death and survival. This molecule has the potential to treat alcohol-associated hepatitis and metabolic dysfunction-associated steatohepatitis, two significant unmet medical needs.
In addition to its lead candidate, Durect Corporation has a diverse portfolio of products, including POSIMIR, a post-surgical pain management solution that delivers bupivacaine over three days, and PERSERIS, an injectable suspension for the treatment of schizophrenia. The companys product pipeline is complemented by strategic collaborations with renowned institutions, such as Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited.
From a technical analysis perspective, DRRX has been trending downward, with its last price of $0.54 being below its SMA20, SMA50, and SMA200. The ATR indicates a relatively high volatility of 13.87%. Given the current market conditions and the companys fundamental data, including a market cap of $19.17M and a negative RoE, it is likely that the stock will continue to face downward pressure.
Using a combination of technical and fundamental analysis, a possible forecast for DRRX is that it may continue to trade within a narrow range, potentially between $0.45 and $0.65, in the short term. However, if the company announces positive topline results for larsucosterol or secures a strategic partnership, the stock could experience a significant upward surge. Conversely, if the company faces regulatory setbacks or fails to meet its clinical trial endpoints, the stock may continue to decline. As such, investors should closely monitor the companys progress and adjust their strategies accordingly.
DRRX Stock Overview
| Market Cap in USD | 59m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2000-09-28 |
DRRX Stock Ratings
| Growth Rating | -50.3% |
| Fundamental | 34.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 4.36% |
| Analyst Rating | 4.33 of 5 |
DRRX Dividends
Currently no dividends paidDRRX Growth Ratios
| Growth Correlation 3m | 76.5% |
| Growth Correlation 12m | -29.8% |
| Growth Correlation 5y | -92.7% |
| CAGR 5y | -32.34% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.39 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | 17.13 |
| Beta | 0.020 |
| Volatility | 113.34% |
| Current Volume | 2787.7k |
| Average Volume 20d | 531k |
| Stop Loss | 1.8 (-5.8%) |
| Signal | -1.49 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-3.48m TTM) > 0 and > 6% of Revenue (6% = 188.9k TTM) |
| FCFTA -1.53 (>2.0%) and ΔFCFTA -37.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.84% (prev -23.52%; Δ 19.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -1.12 (>3.0%) and CFO -14.0m <= Net Income -3.48m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (31.2m) change vs 12m ago 0.40% (target <= -2.0% for YES) |
| Gross Margin 80.59% (prev 80.80%; Δ -0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 14.87% (prev 28.17%; Δ -13.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.45 (EBITDA TTM -12.6m / Interest Expense TTM 1.70m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 33.99
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -34.98% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.44 = 2.40 |
| 5. Debt/Ebitda -0.14 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -70.85% = -2.50 |
| 8. Rev. Trend -85.88% = -6.44 |
| 9. EPS Trend 60.60% = 3.03 |
What is the price of DRRX shares?
Over the past week, the price has changed by -2.55%, over one month by +0.00%, over three months by +202.41% and over the past year by +22.44%.
Is Durect a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DRRX is around 1.58 USD . This means that DRRX is currently overvalued and has a potential downside of -17.28%.
Is DRRX a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DRRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.5 | 30.9% |
| Analysts Target Price | 2.5 | 30.9% |
| ValueRay Target Price | 1.7 | -9.9% |
Last update: 2025-09-08 04:36
DRRX Fundamental Data Overview
CCE Cash And Equivalents = 6.50m USD (Cash And Short Term Investments, last quarter)
P/S = 35.7957
P/B = 17.0294
P/EG = -0.46
Beta = 0.928
Revenue TTM = 3.15m USD
EBIT TTM = -12.7m USD
EBITDA TTM = -12.6m USD
Long Term Debt = 652.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.10m USD (from shortTermDebt, last quarter)
Debt = 1.75m USD (Calculated: Short Term 1.10m + Long Term 652.0k)
Net Debt = -4.75m USD (from netDebt column, last quarter)
Enterprise Value = 54.6m USD (59.3m + Debt 1.75m - CCE 6.50m)
Interest Coverage Ratio = -7.45 (Ebit TTM -12.7m / Interest Expense TTM 1.70m)
FCF Yield = -34.98% (FCF TTM -19.1m / Enterprise Value 54.6m)
FCF Margin = -606.3% (FCF TTM -19.1m / Revenue TTM 3.15m)
Net Margin = -110.5% (Net Income TTM -3.48m / Revenue TTM 3.15m)
Gross Margin = 80.59% ((Revenue TTM 3.15m - Cost of Revenue TTM 611.0k) / Revenue TTM)
Tobins Q-Ratio = -0.09 (set to none) (Enterprise Value 54.6m / Book Value Of Equity -603.8m)
Interest Expense / Debt = 76.46% (Interest Expense 1.34m / Debt 1.75m)
Taxrate = 21.0% (US default)
NOPAT = -12.7m (EBIT -12.7m, no tax applied on loss)
Current Ratio = 0.98 (Total Current Assets 7.77m / Total Current Liabilities 7.89m)
Debt / Equity = 0.44 (Debt 1.75m / last Quarter total Stockholder Equity 3.94m)
Debt / EBITDA = -0.14 (Net Debt -4.75m / EBITDA -12.6m)
Debt / FCF = -0.09 (Debt 1.75m / FCF TTM -19.1m)
Total Stockholder Equity = 4.91m (last 4 quarters mean)
RoA = -27.86% (Net Income -3.48m, Total Assets 12.5m )
RoE = -70.85% (Net Income TTM -3.48m / Total Stockholder Equity 4.91m)
RoCE = -228.1% (set to none) (Ebit -12.7m / (Equity 4.91m + L.T.Debt 652.0k))
RoIC = -171.1% (set to none) (NOPAT -12.7m / Invested Capital 7.41m)
WACC = unknown (E(59.3m)/V(61.1m) * Re(6.09%)) + (D(1.75m)/V(61.1m) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 2.89%
Discount Rate = 6.09% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -19.1m)
EPS Correlation: 60.60 | EPS CAGR: 2.88% | SUE: 0.45 | # QB: False
Revenue Correlation: -85.88 | Revenue CAGR: -69.75%
Additional Sources for DRRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle